Bibliografía del artículo
1. Biasi GM, Froio A, Diethrich EB e col. Carotid plaque echolucency increases the risk of stroke in carotid stenting: the Imaging in Carotid Angioplasty and Risk of Stroke (ICAROS) Study. Circulation 110:756-762, 2004.
2. Ambrose JA, Winters SL, Arora RR e col. Coronary angiographic morphology in myocardial infarction: a link between the pathogenesis of unstable angina and myocardial infarction. Journal of the American College of Cardiology 6:1233-1238, 1985.
3. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. The New England Journal of Medicine 4:242-250, 1992.
4. Fuster V, Badimon L, Cohen M, Ambrose J, Badimon JJ, Chesebro JH. Insights into the pathogenesis of acute ischemic syndromes. Circulation 77:1213-1220, 1988.
5. Ballotta E, Giau G, Renon L. Carotid plaque gross morphology and clinical presentation: a prospective study of 457 carotid artery specimens. J Surg Res 89:78-84, 2000.
6. Ogawa M, Ishino S, Mukai T e col. 18F-FDG Accumulation in Atherosclerotic Plaques: Immunohistochemical and PET Imaging Study. The Journal of Nuclear Medicine 45:1245-1250, 2004.
7. Rudd JHF, Warburton EA, Fryer TD e col. Imaging Atherosclerotic Plaque Inflammation With [18F]-Fluorodeoxyglucose Positron Emission Tomography. Circulation 105:2708-2711, 2002.
8. Yusuf S, Reddy S, Ôunpuu S, Anand S. Global Burden of Cardiovascular Diseases Part I: General Considerations, the Epidemiologic Transition, Risk Factors, and Impact of Urbanization. Circulation 104:2746-2753, 2001.
9. Oliveira R, Santos D, Ferreira D, Coelho P, Veiga F. Preparações radiofarmacêuticas e suas aplicações. Revista Brasileira de Ciências Farmacêuticas 42:151-165, 2006.
10. Yu S. Review of 18F-FDG synthesis and quality control. Biomedical Imaging and Intervention Journal 57:1-11, 2006.
11. Wiebe LI. PET radiopharmaceuticals for metabolic imaging in oncology. International Congress Series 1264:53-76, 2004.
12. Feyter PJ, Serruys PW, Davies MJ, Richardson P, Lubsen J, Oliver MF. Quantitative coronary angiography to measure progression and regression of coronary atherosclerosis. Value, limitations, and implications for clinical trials. Circulation 84:412-423, 1991.
13. Giroud D, Li JM, Urban P, Meier B, Rutishauer W. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 69:729-732, 1992.
14. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl JMed 316:1371-1375, 1987.
15. Hansson GK. Atherosclerosis-an immune disease: the Anitschkov Lecture 2007. Atherosclerosis 202:2-10, 2009.
16. Kolodgie FD, Virmani R, Burke AP e col. Pathologic assessment of the vulnerable human coronary plaque. Heart 90:1385-1391, 2004.
17. Shah PK. Inflammation and plaque vulnerability. Cardiovasc Drugs Ther 23:31-40, 2009.
18. Bleeker-Rovers CP, Vos FJ, Corstens FH, Oyen WJ. Imaging of infectious diseases using [18F] fluorodeoxyglucose PET. Q J Nucl Med Mol Imaging 52:17-29, 2008.
19. Zhang Z, Machac J, Helft G e col. Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation. BMC Nucl Med 6:3, 2006.
20. Fischbach FT, Dunning MB III. Manual of Laboratory and Diagnostic Tests. 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2009.
21. Lederman RJ, Raylman RR, Fisher SJ e col. Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG). Nucl Med Commun 22:747-753, 2001.
22. Davies JR, Izquierdo-Garcia D, Rudd JH e col. FDG-PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis. Int J Cardiovasc Imaging 26:41-48, 2010.
23. Ogawa M, Magata Y, Kato T e col. Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. J Nucl Med 47:1845-1850, 2006.
24. Sheikine Y, Akram K. FDG-PET imaging of atherosclerosis: Do we know what we see? Atherosclerosis 211:371-380, 2010.
25. Davies JR, Rudd JH, Weissberg PL. Molecular and Metabolic Imaging of Atherosclerosis. The Journal of Nuclear Medicine 45:1898-1907, 2004.
26. Basu S, Zhuang H, Alavi A. Imaging of lower extremity artery atherosclerosis in diabetic foot: FDG-PET imaging and histopathological correlates. Clin Nucl Med 32:567-568, 2007.
27. Tahara N, Kai H, Ishibashi M e col. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 48:1825-1831, 2006.
28. Tatsumi M, Cohade C, Nakamoto Y, Wahl RL. Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology 229:831-837, 2003.
29. Yun M, Jang S, Cucchiara A, Newberg AB, Alavi A. 18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med 32:70-76, 2002.